Literature DB >> 17163678

Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.

Anu R Sawkar1, Martina Schmitz, Klaus-Peter Zimmer, David Reczek, Tim Edmunds, William E Balch, Jeffery W Kelly.   

Abstract

Point mutations in the lysosomal hydrolase, glucocerebrosidase (GC), can cause Gaucher disease, a common lysosomal storage disease. Several clinically important GC mutations impede folding in the endoplasmic reticulum (ER) and target these enzymes for ER-associated degradation (ERAD). The removal of these misfolded proteins decreases the lysosomal concentration of GC, which results in glucosylceramide accumulation. The most common GC variant, N370S, and other clinically relevant variants, G202R and L444P, exhibit different cellular localization patterns in patient-derived fibroblasts. We show that these distributions can be altered by manipulation of the ER folding environment, either by chemical chaperones or by temperature shifts. N370S, L444P, and G202R GC are destabilized in the neutral pH environment of the ER, rendering them prone to ERAD. Fibroblasts harboring the G202R and L444P GC mutations grown at 30 degrees C localize the mutant proteins to the lysosome, and this increases total GC activity. Both of these temperature-sensitive mutants appear to be stable at 37 degrees C once they are trafficked to the low pH environment of the lysosome. Chemical chaperones correct the ER instability and significant ER retention of G202R GC. N370S is also destabilized under ER simulating conditions, a deficiency that is corrected by chemical chaperone binding. These data clearly show manipulating the ER environment with chemical chaperones increases the lysosomal concentration of partially active GC variants and suggest that small molecules could be used to treat Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163678     DOI: 10.1021/cb600187q

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  48 in total

1.  Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.

Authors:  Jie Lu; Chunzhang Yang; Masako Chen; Donald Y Ye; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism.

Authors:  Mustafa Kamani; Murugesapillai Mylvaganam; Robert Tian; Brigitte Rigat; Beth Binnington; Clifford Lingwood
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

Authors:  Susan D Orwig; Yun Lei Tan; Neil P Grimster; Zhanqian Yu; Evan T Powers; Jeffery W Kelly; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-11-14       Impact factor: 3.162

Review 4.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

5.  Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases.

Authors:  Fan Wang; Wensi Song; Giovanna Brancati; Laura Segatori
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

6.  Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.

Authors:  Richard J Nowak; Gregory D Cuny; Sungwoon Choi; Peter T Lansbury; Soumya S Ray
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

7.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

8.  Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease.

Authors:  Manoj Kumar Pandey; Reena Rani; Wujuan Zhang; Kenneth Setchell; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2012-04-30       Impact factor: 4.797

9.  Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.

Authors:  Gholamreza Babajani; Michael B Tropak; Don J Mahuran; Allison R Kermode
Journal:  Mol Genet Metab       Date:  2012-04-26       Impact factor: 4.797

Review 10.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.